Responses
Extended report
Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response
Compose a Response to This Article
Other responses
No responses have been published for this article.